Target intelligence / Profile preview

Spleen invigoration

Molecular classification
Other
01

Overview

Spleen invigoration, or 'Jianpi,' is a fundamental therapeutic principle in Traditional Chinese Medicine (TCM) rather than a discrete molecular target like a protein or receptor [1]. In TCM theory, the 'Spleen' refers to a functional system responsible for digestion, nutrient absorption, and the distribution of energy (Qi), and its dysfunction leads to 'Spleen Qi Deficiency' characterized by fatigue and digestive distress [2]. Scientific investigations into this concept suggest that spleen-invigorating agents, such as Sijunzi Decoction, work by modulating the gut-microbiota-immune axis and regulating gastrointestinal motility through hormones like gastrin [3]. These agents often contain active compounds like ginsenosides and atractylenolides that exhibit anti-inflammatory and metabolic-regulating properties [4]. From a modern biotech perspective, 'Spleen invigoration' represents a holistic pharmacological effect or clinical outcome rather than a specific druggable molecule, making it 'incorrect' when categorized as a standard therapeutic target [5].

Other names
JianpiTonifying the SpleenSpleen-strengtheningJianpi YiqiSupplementing Spleen Qi
02

Mechanism of action

Spleen invigoration involves a multi-target pharmacological approach that modulates gastrointestinal hormones (e.g., gastrin, motilin), restores gut microbiota diversity, enhances the activity of digestive enzymes (e.g., amylase), and regulates the hypothalamic-pituitary-adrenal (HPA) axis to improve metabolic and immune homeostasis.

03

Biological functions

DigestionNutrient absorptionImmune responseMetabolismFluid homeostasis
04

Disease associations

Spleen Qi DeficiencyGastrointestinal disordersChronic fatigue syndromeAnorexiaMalabsorption
05

Safety considerations

Lack of molecular specificityPotential for herb-drug interactions with conventional pharmaceuticalsVariability in the standardization of herbal extractsRisk of misdiagnosis if used to treat underlying organic diseases without conventional screening
06

Interacting drugs

Sijunzi Decoction

4 more in the full profile.

07

Biomarkers

D-xylose excretion rateSerum gastrin levelsSerum amylase activityUrine 17-hydroxycorticosteroid (17-OHCS)Interleukin-2 (IL-2)

Beyond the preview

Go deeper on Spleen invigoration.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spleen invigoration.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call